MorphoSys AG announced that its lawsuit against Janssen Biotech and Genmab A/S has been settled. The parties have agreed to drop the mutual claims related to this litigation.
MorphoSys filed a lawsuit in the U.S. District Court of Delaware against Janssen Biotech, and Genmab, A/S in 2016 for patent infringement, and again In 2017, for a second and a third patent. MorphoSys sought reperations for alleged infringement by Janssen’s and Genmab’s daratumumab, a monoclonal antibody for the treatment of multiple myeloma.
MorphoSys is dismissing the claims and did not appeal in the previously-announced court order. Janssen and Genmab are dismissing their counterclaims.